Schlee, Christoph
Uecker, Christine
Bauer, Nina
Koch, Anna K.
Langhorst, Jost
Article History
Received: 5 August 2021
Accepted: 3 December 2021
First Online: 8 March 2022
Declarations
:
: All participants signed an informed consent. The study was approved by the ethics committee of the University of Duisburg-Essen (approval number 15-6554-BO), registered under clinicaltrials.gov (ID: NCT02721823), and was conducted in accordance with the Helsinki Declaration and the Guidelines for Good Clinical Practice.
: Not applicable.
: JL was a speaker for Repha GmbH, Techlab Inc., Falk Foundation, Takeda, Celegene GmbH and Willmar Schwabe and received research funding from Repha GmbH, Techlab Inc., Falk Foundation and Willmar Schwabe. No conflict of interest: CS., CU., NB, AKK. The sponsors had no role in the design, execution, interpretation or writing of the study.